参附注射液治疗脓毒症休克大鼠前后sCD163的变化

sCD163 changes in septic rats before and after treatment with Shenfu injection

目的:观察参附注射液联合西药治疗脓毒症休克大鼠的疗效。通过检测脓毒症休克大鼠用药前后血清sCD163数值的变化来了解参附注射液联合西药治疗脓毒症休克大鼠的疗效及重症脓毒症预后的评估。同时对在脓毒症中sCD163的作用机制进行探讨。方法:选取SPF级健康SD雄性大鼠60只,制作脓毒症休克大鼠模型,观察单用西药、单用参附注射液和参附注射液联合西药治疗前后大鼠sCD163、降钙素原、Lac的变化。结果:参附注射液联合西药治疗脓毒症休克大鼠前后6 h sCD163的变化具有统计学意义,联合治疗组优于单纯参附注射液或单纯西药组。结论:参附注射液能对抗细菌内毒素,对心肌细胞有正性肌力作用,sCD163做为临床脓毒症观察的敏感指标有望广泛应用于临床脓毒症休克治疗。

OBJECTIVE To investigate efficacy of Shenfu injection combined with western medicine on septic rats and evaluate prognosis of severe septicaemia by determining serum sCD163 changes before and after treatment,and study action mechanism of sCD163 in septicaemia and a new biomarker for diagnosis of sepsis.METHODS Sixty SD rats made to be septic models were randomly divided into five groups,serum samples before and after treatment were collected to test changes of sCD163,procalcitonin and Lac.RESULTS Value of sCD163 significantly decreased in group administering Shenfu injection combined with western medicine.The efficacy was superior to that of Shenfu injection or western medicine alone.CONCLUSION Shenfu injection can fight against bacterial endotoxin and has positive inotropic effects.sCD163 used as a biomarker of sepsis might be a treatment target.